2012
New Pharmacotherapy for Hepatitis C
Assis DN, Lim JK. New Pharmacotherapy for Hepatitis C. Clinical Pharmacology & Therapeutics 2012, 92: 294-305. PMID: 22850602, DOI: 10.1038/clpt.2012.103.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsDrug Therapy, CombinationHepacivirusHepatitis CHIV InfectionsHumansLiverOligopeptidesProlineConceptsHepatitis CChronic hepatitis C infectionMajor global public health burdenGlobal public health burdenViral eradication ratesHepatitis C infectionProtease inhibitors boceprevirPublic health burdenDrug Administration approvalHepatitis C virus proteaseHCV pharmacotherapyC infectionEradication rateViral eradicationImproved tolerabilitySubstantial morbidityAntiviral therapyAdministration approvalNew pharmacotherapiesHealth burdenSuperior efficacyAntiviral agentsUS FoodPharmacotherapyShort duration
2011
Successful Treatment of Fibrosing Cholestatic Hepatitis After Liver Transplantation
Cimsit B, Assis D, Caldwell C, Arvelakis A, Taddei T, Kulkarni S, Schilsky M, Emre S. Successful Treatment of Fibrosing Cholestatic Hepatitis After Liver Transplantation. Transplantation Proceedings 2011, 43: 905-908. PMID: 21486625, DOI: 10.1016/j.transproceed.2011.02.034.Peer-Reviewed Case Reports and Technical NotesConceptsLiver allograft rejectionHepatitis C virusRenal graft rejectionAllograft rejectionHCV recurrenceCholestatic hepatitisGraft rejectionHCV RNAPatient survivalEnd-stage liver disease (MELD) scoreOne-year patient survivalIFN/RBV therapyFIBROSING CHOLESTATIC HEPATITISHistologic HCV recurrenceIFN/ribavirinOne-year graftSuccessful salvage strategiesTime of OLTHCV RNA levelsLiver Disease scoreAnti-HCV therapyCohort of patientsEarly graft failureFCH groupOLT recipients